ライフサイエンスコーパス: visceral adipose tissue

1 s (body mass index, waist circumference, and visceral adipose tissue).

2 d arteries, subcutaneous adipose tissue, and visceral adipose tissue.

3 lipoprotein lipase and up-regulated Socs3 in visceral adipose tissue.

4 storage, perhaps by suppressing lipolysis in visceral adipose tissue.

5 changes in body weight, body composition, or visceral adipose tissue.

6 nd constitutively at mucosal surfaces and in visceral adipose tissue.

7 nd were highly correlated with each other in visceral adipose tissue.

8 s were observed in human subcutaneous versus visceral adipose tissue.

9 pically seen in diabetes, and hypertrophy of visceral adipose tissue.

10 d secretory phenotype (SASP) specifically in visceral adipose tissue.

11 IL-1beta levels and decreased ILC markers in visceral adipose tissue.

12 sulin sensitivity and collagen deposition in visceral adipose tissue.

13 = 0.02) was attenuated after controlling for visceral adipose tissue.

14 ated genes as compared with subcutaneous and visceral adipose tissues.

15 5, after adjustment for changes in weight or visceral adipose tissue].

16 Visceral adipose tissue, a marker of central adiposity,

17 s we measured are not a predominant cause of visceral adipose tissue accumulation.

18 d body composition [total, subcutaneous, and visceral adipose tissue; adipose tissue-free mass (ATFM)

19 ammatory pathways were measured in liver and visceral adipose tissue after 10 weeks.

20 Similarly, no difference was found in visceral adipose tissue and abdominal subcutaneous fat a

21 as a target of nuclear receptor PPARgamma in visceral adipose tissue and as a critical factor in adip

22 appears to be preferentially produced by the visceral adipose tissue and has insulin mimetic actions.

23 subfraction particle size, and reduction in visceral adipose tissue and liver fat, independent of we

24 Primary end points were changes in visceral adipose tissue and liver fat.

25 dysglycemia and dyslipidemia independent of visceral adipose tissue and other obesity measures.

26 Visceral adipose tissue and subcutaneous abdominal adipo

27 Visceral adipose tissue and subcutaneous adipose tissue

28 roduction of antiinflammatory eicosanoids in visceral adipose tissue and subcutaneous adipose tissue

29 We measured the visceral adipose tissue and subcutaneous adipose tissue

30 cord and used by two operators to quantitate visceral adipose tissue and subcutaneous adipose tissue

31 M1/M2 macrophages within the peritoneal and visceral adipose tissues and higher percentages of TNF(+

32 Incubation of inflamed Ob visceral adipose tissues and human macrophages with RvD1

33 ased Wnt expression in both subcutaneous and visceral adipose tissues and impaired adipogenic differe

34 ndependent of coronary artery calcium score, visceral adipose tissue, and 10-year global cardiovascul

35 e cross-sectional abdominal subcutaneous and visceral adipose tissue, and computed tomography (CT) of

36 tion of limb and trunk fat, subcutaneous and visceral adipose tissue, and increased total cholesterol

37 he change in total abdominal adipose tissue, visceral adipose tissue, and SAT at 24 mo (P = 0.01, 0.0

38 erence (WC), total abdominal adipose tissue, visceral adipose tissue, and subcutaneous adipose tissue

39 and HDL were strongest for WC, MRI-measured visceral adipose tissue, and WHR; in all cases, differen

40 th morbid obesity, and subcutaneous, but not visceral, adipose tissue angiogenic capacity correlated

41 Visceral adipose tissue area (treatment effect [last-val

42 ) at the 25th, 50th, and 75th percentiles of visceral adipose tissue area, respectively (p = 0.001),

43 orts the notion that elevated CCL2 levels in visceral adipose tissue associated with Metabolic Syndro

44 hibited higher expression levels of IL-32 in visceral adipose tissue (AT) as well as in subcutaneous

45 sonance imaging to quantify subcutaneous and visceral adipose tissue (AT).

46 ic-euglycemic clamp with skeletal muscle and visceral adipose tissue biopsies at baseline and at 30 a

47 propria (LP) of the small intestine, brain, visceral adipose tissue, bone marrow (BM), spleen, and t

48 Among the subset of obese participants, visceral adipose tissue, but not abdominal subcutaneous

49 ured by dual-energy X-ray absorptiometry and visceral adipose tissue by computerized tomography.

50 y molecules from other tissues, particularly visceral adipose tissue, can also induce muscle inflamma

51 sue samples (subcutaneous adipose tissue and visceral adipose tissue), collected during surgery after

52 y biomarker expression in three key tissues: visceral adipose tissue, colon (local inflammatory site)

53 elements in the portal vasculature, and even visceral adipose tissue communicate with the controllers

54 d frequency of regulatory T cells (Tregs) in visceral adipose tissue contribute to the propagation of

55 Accumulation of visceral adipose tissue correlates with elevated inflamm

56 An excess of visceral adipose tissue could be involved as a modulator

57 Vaspin (visceral adipose tissue-derived serine protease inhibito

58 Visceral adipose tissue-derived serpin (vaspin), serpin

59 ance of normal weight for approximately 1 y, visceral adipose tissue distribution in AN patients was

60 elial interactions and macrophage content of visceral adipose tissue due to Psgl-1 deficiency was als

61 d to enhanced insulin signaling in liver and visceral adipose tissue (epididymal white adipose tissue

62 er additional adjustment for body weight and visceral adipose tissue, except for pericardial fat and

63 Visceral adipose tissue exhibited significantly blunted

64 creased the expression of lipogenic genes in visceral adipose tissue explants and intracellular calci

65 Finally, visceral adipose tissue explants were cultured with reco

66 creased SPARC production dose dependently in visceral adipose tissue explants, while glucose decrease

67 resulted in hyperresistinemia and increased visceral adipose tissue expression of suppressor of cyto

68 mote the resolution of inflammation in human visceral adipose tissue from obese (Ob) patients.

69 Visceral adipose tissue GPR55 correlated positively with

70 Whether visceral adipose tissue has a uniquely powerful associat

71 ty and subcutaneous body fat, differences in visceral adipose tissue have not been evaluated.

72 nt for more than 20% of stromal cells within visceral adipose tissues; however, their functions in th

73 We biopsied paired subcutaneous and visceral adipose tissue in 40 obese subjects (body mass

74 rotein A3 (Foxa3) regulates the expansion of visceral adipose tissue in high-fat diet regimens; howev

75 ssed in brown adipose tissue in rodents, and visceral adipose tissue in humans.

76 ne variant have an impaired capacity to lose visceral adipose tissue in response to prolonged caloric

77 There was significantly more visceral adipose tissue in the subgroup of HIV-infected

78 study was performed to elucidate the role of visceral adipose tissue in whole-body glucose homeostasi

79 ake is reduced in subcutaneous abdominal and visceral adipose tissues in IGT(+) directly associated w

80 cient mice have multiple histopathologies in visceral adipose tissue, including increased adipocyte d

81 AHR, lung and visceral adipose tissue inflammation, humoral response,

82 Visceral adipose tissue is a major site for expression o

83 Chronic inflammation in visceral adipose tissue is considered a key element for

84 It has been hypothesized that visceral adipose tissue lipolysis releases excess FFAs i

85 We conclude that the contribution of visceral adipose tissue lipolysis to hepatic FFA deliver

86 effect of the Trp64Arg variant on total and visceral adipose tissue loss, insulin sensitivity, and c

87 DPP-4i reduced visceral adipose tissue macrophage content (adipose tiss

88 minal subcutaneous adipose tissue, increased visceral adipose tissue, marked IR, dyslipidemia, and fa

89 ific CD1d deletion decreased the size of the visceral adipose tissue mass and enhanced insulin sensit

90 Iron supplemented mice had lower visceral adipose tissue mass estimated by epididymal fat

91 though whole-body fat mass was not affected, visceral adipose tissue mass tended to decrease after th

92 tage of fat mass, total adipose tissue mass, visceral adipose tissue mass, and superficial adipose ti

93 s have been specifically linked to increased visceral adipose tissue mass.

94 etion of a host of inflammatory factors from visceral adipose tissue may contribute to the increased

95 sment of body fat distribution, particularly visceral adipose tissue, may be important for accurate r

96 Tesamorelin significantly reduced visceral adipose tissue (mean change, -34 cm2 [95% CI, -

97 istance and hypertriglyceridemia and affects visceral adipose tissue metabolism by a mechanism involv

98 Visceral adipose tissue MMP14 expression correlated stro

99 odel of diet-induced obesity, Tregs from the visceral adipose tissue of hyperinsulinemic, obese mice

100 e phospho-Akt/Akt ratio, was detected in the visceral adipose tissue of iron overloaded mice, and gen

101 n inflammatory (type 1) CD11c(+) ATMs in the visceral adipose tissue of Mgl1(-/-) mice.

102 s (ILC2s) was also observed in the lungs and visceral adipose tissue of Nfil3-deficient mice, reveali

103 ols, GS-HNE and GS-DHN were more abundant in visceral adipose tissue of ob/ob mice and diet-induced o

104 Similarly, in whole animals, visceral adipose tissue of STAMP2(-/-) mice exhibits ove

105 vanced ovarian cancer usually spreads to the visceral adipose tissue of the omentum.

106 bers were decreased in both subcutaneous and visceral adipose tissue of TRPC1 KO mice fed a HF diet a

107 risk, especially in women, correlating with visceral adipose tissue (P < 0.0001) and triglycerides (

108 io (P < 0.006), total trunk fat (P < 0.003), visceral adipose tissue (P < 0.006), and intramuscular a

109 hma had increased macrophage infiltration of visceral adipose tissue (P < 0.01), with increased expre

110 ngest correlate of serum triacylglycerol was visceral adipose tissue (P = 0.002 for both women and me

111 2 years) underwent assessment of fat depots (visceral adipose tissue, pericardial adipose tissue, and

112 eous adipose tissue (ingSAT) and perigonadal visceral adipose tissue (pgVAT) is promoted by the deple

113 Pericardial fat, intrathoracic fat, and visceral adipose tissue quantified from multidetector co

114 muscle (r = 0.825; P = .003), and abdominal visceral adipose tissue (r = 0.820; P = .004).

115 intrathoracic fat (r=0.17 to 0.31, P<0.001), visceral adipose tissue (r=0.19 to 0.36, P<0.001), body

116 intrathoracic fat (r=0.25 to 0.37, P<0.001), visceral adipose tissue (r=0.24 to 0.45, P<0.001), body

117 er insulin levels and higher subcutaneous-to-visceral adipose tissue ratio and may protect from disea

118 In this review, we discuss the roles of visceral adipose tissue's salient leukocyte lineages in

119 Abdominal subcutaneous and visceral adipose tissue (SAT and VAT) were reduced (494

120 loaded mice, and gene expression analysis of visceral adipose tissue showed that an iron-enriched die

121 d tissue-Treg populations-those operating in visceral adipose tissue, skeletal muscle, and the coloni

122 ale sex, alanine aminotransferase levels and visceral adipose tissue/subcutaneous adipocyte size rati

123 er 90-day mortality than patients with lower visceral adipose tissue/subcutaneous adipose tissue (log

124 eous adipose tissue than in those with lower visceral adipose tissue/subcutaneous adipose tissue (p =

125 Sepsis patients with higher visceral adipose tissue/subcutaneous adipose tissue had

126 apy, and ICU stay in patients in the highest visceral adipose tissue/subcutaneous adipose tissue quar

127 t covariates using Cox regression, increased visceral adipose tissue/subcutaneous adipose tissue quar

128 os of 2.01 (95% CI, 1.01-3.99) for the third visceral adipose tissue/subcutaneous adipose tissue quar

129 and 2.32 (95% CI, 1.15-4.69) for the highest visceral adipose tissue/subcutaneous adipose tissue quar

130 e levels was greater in patients with higher visceral adipose tissue/subcutaneous adipose tissue than

131 Visceral adipose tissue/subcutaneous adipose tissue was

132 Increased mortality for patients with higher visceral adipose tissue/subcutaneous adipose tissue was

133 and subcutaneous adipose tissue but greater visceral adipose tissue than HIV-infected patients witho

134 Pericardial fat is visceral adipose tissue that possesses inflammatory prop

135 Addition of visceral adipose tissue to a multivariable model that in

136 est that TNMD acts as a protective factor in visceral adipose tissue to alleviate insulin resistance

137 between men and women in the contribution of visceral adipose tissue to hepatic FFA delivery, most st

138 eous adipose tissue areas and calculated the visceral adipose tissue-to-subcutaneous adipose tissue r

139 Visceral obesity, defined by a high visceral adipose tissue-to-subcutaneous adipose tissue r

140 of fatty acids released during lipolysis of visceral adipose tissue triglycerides to portal and syst

141 1000 kcal) were associated with decreases in visceral adipose tissue (VAT) (r = -0.29, P = 0.02, and

142 PAI-1 was positively associated with visceral adipose tissue (VAT) (r = 0.49, P < 0.01), SAAT

143 maging and spectroscopy were used to measure visceral adipose tissue (VAT) and liver fat fraction (LF

144 zebrafish induced hyperplastic morphology in visceral adipose tissue (VAT) and reduced lipid storage.

145 The cellular composition of visceral adipose tissue (VAT) and release of cytokines b

146 The effect of visceral adipose tissue (VAT) and subcutaneous adipose t

147 was to examine the differences in abdominal visceral adipose tissue (VAT) and subcutaneous adipose t

148 Visceral adipose tissue (VAT) and subcutaneous adipose t

149 ciation of habitual SSB intake and change in visceral adipose tissue (VAT) and subcutaneous adipose t

150 Visceral adipose tissue (VAT) and subcutaneous adipose t

151 etic resonance spectroscopy and LV function, visceral adipose tissue (VAT) and subcutaneous adipose t

152 bolic and transcriptomic differences between visceral adipose tissue (VAT) and subcutaneous adipose t

153 Visceral adipose tissue (VAT) and subcutaneous adipose t

154 accumulation and activation of leukocytes in visceral adipose tissue (VAT) and ultimately other tissu

155 Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) are associated with advers

156 ms to measure total adipose tissue (TAT) and visceral adipose tissue (VAT) at the umbilicus (L4 verte

157 ormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12 month

158 Visceral adipose tissue (VAT) compartments may confer in

159 During obesity, the hypertrophy of visceral adipose tissue (VAT) contributes to muscle dysf

160 ite ample evidence to confirm that increased visceral adipose tissue (VAT) deposition occurs with obe

161 omography to evaluate subcutaneous (SAT) and visceral adipose tissue (VAT) distribution and had anthr

162 Visceral adipose tissue (VAT) has been identified as a h

163 Eosinophils in visceral adipose tissue (VAT) have been implicated in me

164 nts of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in children treated for ma

165 e juice (OJ) on weight loss and reduction of visceral adipose tissue (VAT) in overweight and obese ad

166 growth factor binding protein (IGFBP) 3, and visceral adipose tissue (VAT) in subjects with adenomato

167 ariate analysis, plasma adiponectin, AD, and visceral adipose tissue (VAT) independently predicted IH

168 tion of non-canonical WNT5A/PCP signaling to visceral adipose tissue (VAT) inflammation and associate

169 zed by T cell and macrophage infiltration of visceral adipose tissue (VAT) is a hallmark of obesity-a

170 In several white populations, visceral adipose tissue (VAT) is a risk factor for devel

171 Visceral adipose tissue (VAT) is an important risk facto

172 Visceral adipose tissue (VAT) is an important risk facto

173 It is well established that visceral adipose tissue (VAT) is associated with increas

174 In obese individuals, visceral adipose tissue (VAT) is the seat of chronic low

175 ntervention on food intake, body weight, and visceral adipose tissue (VAT) mass; plasma, lipids (chol

176 aluated by quantitative real-time PCR in the visceral adipose tissue (VAT) of 35 obese subjects under

177 d expression of some adipogenesis markers in visceral adipose tissue (VAT) of HFD-fed M-JAK2(-/-) mic

178 )CD4(+) regulatory T (Treg) cells resides in visceral adipose tissue (VAT) of lean mice, especially i

179 driving the adaptive Th17 response in human visceral adipose tissue (VAT) of metabolically unhealthy

180 r fitness, percentage of body fat (%BF), and visceral adipose tissue (VAT) of obese adolescents.

181 grouped them by MRI-derived visceral fat to visceral adipose tissue (VAT) plus SAT (VAT/VAT+SAT) rat

182 Chronic inflammation in visceral adipose tissue (VAT) precipitates the developme

183 Men are believed to have more visceral adipose tissue (VAT) than women have, but studi

184 ombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HIV-infected pat

185 Subcutaneous adipose tissue (SAT) volume, visceral adipose tissue (VAT) volume, and VAT/SAT ratio

186 uently chosen to approximate total abdominal visceral adipose tissue (VAT) volume, but growing eviden

187 82 had subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) volumes measured by multid

188 Visceral adipose tissue (VAT) was measured by computed t

189 Liver fat, visceral adipose tissue (VAT), abdominal subcutaneous ad

190 les of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), and phenotypes and functi

191 midthigh MRI slice to assess whole-body SM, visceral adipose tissue (VAT), and subcutaneous adipose

192 ominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), assessed by multidetector

193 ed with an influx of pathogenic T cells into visceral adipose tissue (VAT), but the mechanisms regula

194 have increased body weight, amount of total visceral adipose tissue (VAT), fasting blood glucose and

195 In visceral adipose tissue (VAT), HFD exposure determined a

196 IR subjects exhibited significantly greater visceral adipose tissue (VAT), intrahepatic lipid (IHL),

197 Visceral adipose tissue (VAT), subcutaneous abdominal ad

198 mass index (BMI) and areas and densities of visceral adipose tissue (VAT), subcutaneous adipose tiss

199 l-body skeletal muscle (SM) and increases in visceral adipose tissue (VAT), subcutaneous adipose tiss

200 ) in T cells in skewing adaptive immunity in visceral adipose tissue (VAT), thereby contributing to d

201 Abdominal subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), thigh SAT, and thigh inte

202 Visceral adipose tissue (VAT), which is linked with the

203 formation, we used a novel ex vivo system of visceral adipose tissue (VAT)-condition medium-stimulate

204 e and inflammation thought to be caused by a visceral adipose tissue (VAT)-localized reduction in imm

205 ssion in DC/macrophage cell populations from visceral adipose tissue (VAT).

206 mice by activating its Y2 receptor (Y2R) in visceral adipose tissue (VAT).

207 depend on accompanying amounts of abdominal visceral adipose tissue (VAT).

208 ominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT).

209 ibution, and the main specific end point was visceral adipose tissue (VAT).

210 l adipose tissue depots increased except for visceral adipose tissue (VAT).

211 e associated with higher levels of visceral [visceral adipose tissue (VAT)] and deep subcutaneous [de

212 leterious metabolic effects of visceral fat [visceral adipose tissue (VAT)] deposition were challenge

213 Foxp3(+) regulatory T (Treg) cells in visceral adipose tissue (VAT-Treg cells) are functionall

214 4, p<0.0001), HOMA2-IR (r=0.74, p=0.01), and visceral adipose tissue volume (r=0.74, p=0.036).

215 s index (r=0.73, p<0.0001), subcutaneous and visceral adipose tissue volumes (r=0.94 and r=0.87, resp

216 significant differences in subcutaneous and visceral adipose tissue volumes and ratios.

217 However, loss of visceral adipose tissue was 43% lower in carriers of the

218 Visceral adipose tissue was also associated with lower c

219 For women, visceral adipose tissue was an independent predictor of

220 After multivariable adjustment, visceral adipose tissue was associated with cardiovascul

221 After multivariable adjustment, visceral adipose tissue was associated with concentric r

222 Visceral adipose tissue was not associated with adenoma

223 n 2 cm(3) biopsy samples of subcutaneous and visceral adipose tissue were obtained.

224 ractant protein-1, and macrophage content of visceral adipose tissue were reduced in Lepr(db/db),Psgl

225 atio was found in metabolically more harmful visceral adipose tissue when compared to subcutaneous ad

226 of tdTomato-C3aR in the brain, lung, LP, and visceral adipose tissue, whereas it was minor in the spl

227 eding reduces senescent phenotype markers in visceral adipose tissue while attenuating physical impai

228 The association of visceral adipose tissue with MI in women was independent

229 with normal insulin sensitivity and healthy visceral adipose tissue with normal adiponectin function

230 The omentum is a visceral adipose tissue with unique immune functions.